Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 5536-17-4 | Product Number: V0175
Vidarabine
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 9-β-D-Arabinofuranosyl-9H-purin-6-amine
- Adenine 9-β-D-Arabinofuranoside
- 6-Amino-9-β-D-arabinofuranosylpurine
- Ara-A
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 5G |
$61.00
|
1 | 1 | 2 |
|
| 25G |
$184.00
|
1 | 1 | 13 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | V0175 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__0H__1__3N__5O__4 = 267.25 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Hygroscopic |
| CAS RN | 5536-17-4 |
| Reaxys Registry Number | 624881 |
| PubChem Substance ID | 468593117 |
| MDL Number | MFCD00065471 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Specific rotation | -2.0 to -4.0 deg(C=1, DMF) |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 257 °C |
| Maximum Absorption Wavelength | 260(H2O) nm |
GHS
Related Laws:
| RTECS# | AU6200000 |
Transport Information:
| HS Number | 2934.99.9001 |
Application
Vidarabine: An Arabinosyladenine with Ant-Virus and Anti-Cancer Activities
Vidarabine (arabinosyladenine, ara-A) is a synthetic purine nucleoside, and was first synthesized by Lee et al. in 1960. Vidarabine was originally intended as an anti-cancer agent, while the anti-viral activity against herpesvirus and vaccinia virus was reported by Rudder et al in 1965. And also the activity against varicella-zoster virus was reported by Miller et al. in 1968. Vidarabine had a broad-spectrum activity against DNA viruses but little activity against RNA viruses. Vidarabine is converted to the active form vidarabine triphosphate (ara-ATP) which inhibits viral DNA polymerase activity in vitro and in vivo. (The product is for research purpose only.)
References
- Potential Anticancer Agents.1 Xl. Synthesis of the β-Anomer of 9-(D-Arabinofuranosyl)-Adenine
- Inhibitory effect of some nucleosides on the growth of various human viruses in tissue culture.
- Antiviral activity of 9-beta-D-arabinofuranosyladenine. I. Cell culture studies.
- Inhibition of Herpesvirus DNA Synthesis by 9-β-D-Arabinofuranosyladenine in Cellular and Cell-Free Systems
- The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA)
- Vidarabine: a preliminary review of its pharmacological properties and therapeutic use
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.